Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Takeda Begins Phase III Study of Obesity Treatment in Japan
RxTrials Institute Drug Pipeline Alert
Dec. 24, 2008 | Vol. 6 No. 52
Takeda Begins Phase III Study of Obesity Treatment in Japan
Takeda Pharmaceutical has started a Phase III clinical study of ATL-962, a treatment for obesity and related diseases.
The drug is expected to help treat obesity and related diabetes or dyslipidemia in the double-blind Japanese trial, Takeda said. The treatment causes weight loss by reducing digestion and the absorption of fat from the diet.
As part of an agreement with Alizyme, which discovered and created the drug, Takeda is responsible for the development and commercialization of the drug in Japan.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.